BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...HDAC6 inhibitor, in Phase I/II testing to treat multiple myeloma (MM). Karus Therapeutics Ltd. and IkerChem S.L....
BioCentury | Aug 5, 2013
Strategy

Future-proofing MM

...inhibitors or diseases such as non-Hodgkin's lymphoma (NHL). Other companies developing selective HDAC6 inhibitors include IkerChem S.L....
...Summit, N.J. Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. European Hematology Association (EHA), The Hague, the Netherlands IkerChem S.L....
BioCentury | Dec 14, 2009
Emerging Company Profile

Binding site rationale: Sidebar: Corporate Profile

IkerChem S.L. San Sebastian, Spain Technology: Rational design of small molecule therapeutics for cancer and neurodegenerative indications Disease focus: Cancer Clinical status: Preclinical Founded: 2006 by Fernando Cossío and Ana Arrieta University collaborators: None Corporate...
BioCentury | Dec 14, 2009
Emerging Company Profile

IkerChem: Binding site rationale

..."because the inhibitor doesn't completely cover the mouth of the binding site." Thus, he said, IkerChem...
...the entrance to that site. Chauncey declined to disclose which computational tools, techniques or software IkerChem...
...have five compounds in preclinical development and beyond within the next two to three years." IkerChem...
Items per page:
1 - 4 of 4
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...HDAC6 inhibitor, in Phase I/II testing to treat multiple myeloma (MM). Karus Therapeutics Ltd. and IkerChem S.L....
BioCentury | Aug 5, 2013
Strategy

Future-proofing MM

...inhibitors or diseases such as non-Hodgkin's lymphoma (NHL). Other companies developing selective HDAC6 inhibitors include IkerChem S.L....
...Summit, N.J. Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. European Hematology Association (EHA), The Hague, the Netherlands IkerChem S.L....
BioCentury | Dec 14, 2009
Emerging Company Profile

Binding site rationale: Sidebar: Corporate Profile

IkerChem S.L. San Sebastian, Spain Technology: Rational design of small molecule therapeutics for cancer and neurodegenerative indications Disease focus: Cancer Clinical status: Preclinical Founded: 2006 by Fernando Cossío and Ana Arrieta University collaborators: None Corporate...
BioCentury | Dec 14, 2009
Emerging Company Profile

IkerChem: Binding site rationale

..."because the inhibitor doesn't completely cover the mouth of the binding site." Thus, he said, IkerChem...
...the entrance to that site. Chauncey declined to disclose which computational tools, techniques or software IkerChem...
...have five compounds in preclinical development and beyond within the next two to three years." IkerChem...
Items per page:
1 - 4 of 4